OpenAlex
PricingAboutJobs
Log inGet started
Work

The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer

HTML

Year: 2021
Type: article
Source: Clinical Cancer Research
DOI: 10.1158/1078-0432.ccr-20-3725
Authors: Petra Deegen, Oliver Thomas, Olivier Nolan-Stevaux, Shyun Li, Joachim Wahl, Pamela Bogner, Famke Aeffner, Matthias Friedrich, Michael Z. Liao, Katja Matthes, Doris Rau, Benno Rattel, Tobias Raum, Peter Kufer, Angela Coxon, Julie M. Bailis
Institutions: Amgen (Germany), Amgen (United States)
Language: English

Topic: Prostate Cancer Treatment and Research
Subfield: Cancer Research
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: bispecific T-cell engagers, prostate-specific membrane antigen, metastatic castration-resistant prostate cancer, CD3, half-life extension, PSMA-11, enzalutamide, anti-PD-1 therapy, combination therapy, xenograft models, anticancer activity
SDG: Good health and well-being

Open Access status: closed

Funder: Amgen
OpenAlex ID: W3123424129
FWCI: 4.765
Cites: 49
Cited by: 107
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security